Full Press Release Details
CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual
Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--September 9, 2014--BioTime, Inc. (NYSE
MKT: BTX), a biotechnology company that develops and markets products in
the field of regenerative medicine, today announced that Chief Executive
Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 16th
Annual Healthcare Conference at 9:35 a.m. EDT on Wednesday, September
10, 2014. The conference will be held at the New York Palace Hotel in
New York City. Dr. West will provide an update on product development by
BioTime and its subsidiaries.
The live audio webcast will be available at http://wsw.com/webcast/rrshq24/btx.
An archive of the presentation will be available for 90 days.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem
progenitors, HyStem hydrogels, culture media,
and differentiation kits. BioTime is developing Renevia (a HyStem
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications, and is planning
to initiate a pivotal clinical trial around Renevia , in 2014.
The HyStem -based product PremviaTM
is cleared the FDA in the US for use in wound management. In addition,
BioTime has developed Hextend , a blood plasma
volume expander for use in surgery, emergency trauma treatment and other
applications. Hextend is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
HealthCare Corporation, under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
Asterias Biotherapeutics, Inc. is developing pluripotent
stem-cell based therapies in neurology and oncology, including
AST-OPC1 oligodendrocyte progenitor cells in spinal cord injury,
multiple sclerosis and stroke, and AST-VAC2, an allogeneic dendritic
cell-based cancer vaccine. Asterias Series A common stock is traded
under the symbol ASTY.
BioTime Asia, Ltd., a Hong Kong company, may offer and sell
products for research use for BioTime's ESI BIO Division.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology
company focused on developing stem cell-based therapies for retinal
and neurological disorders, including the development of retinal
pigment epithelial cells for the treatment of macular degeneration,
and treatments for multiple sclerosis.
ESI BIO is the research and product marketing division of
BioTime, providing stem cell researchers with products and
technologies to enable them to translate their work into the clinic,
including PureStem progenitors and HyStem
LifeMap Sciences, Inc. markets, sells, and distributes GeneCards ,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery
database of embryonic development, stem cell research, and
regenerative medicine, and MalaCards, the human disease
LifeMap Solutions, Inc. is a subsidiary of LifeMap Sciences
focused on developing mobile health (mHealth) products.
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer, including PanC-Dx , with three
clinical trials currently underway.
OrthoCyte Corporation is developing therapies to treat
orthopedic disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a
variety of cardiovascular and related ischemic disorders, as well as
products for research using cell reprogramming technology.
BioTime stock is traded on the NYSE Market exchange, ticker BTX. For
more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube, and
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
Share this news via Twitter:
Click to Tweet: BioTime CEO Dr. Michael West to Present at
Rodman & Renshaw 16th Annual Healthcare Conference; webcast link http://bit.ly/1u6pXgI
Judith Segall, 510-521-3390, ext 301